Ekso Bionics, Inc

EnColl Corporation, established in 1994 and based in Fremont, CA, specializes in the development, manufacture, and marketing of high-purity Type-I collagen-based products. Utilizing patented technology, the company produces collagen that is 99% pure, ensuring minimal immunogenicity and high bioactivity for various medical applications, including wound healing and tissue regeneration. One of EnColl's flagship products, Helicoll, serves as an acellular skin substitute designed to promote blood vessel regeneration and support cellular migration, making it a valuable tool in wound management. Committed to stringent quality control standards, EnColl's products cater to a wide range of biomedical applications and have demonstrated significant efficacy in clinical settings. Generated from the website

Pionyr Immunotherapeutics, Inc., a biotechnology company based in South San Francisco, CA, was acquired by Ikena Oncology, Inc. in August 2023. Their innovative Myeloid Tuning programs aim to enhance the immune system's anti-tumor response by modifying the cellular infiltrate of the tumor microenvironment. With clinical programs targeting TREM2 and TREM1, Pionyr focuses on selectively depleting and reprogramming tumor-associated macrophages responsible for immunosuppression, demonstrating safety in Phase 1a b trials alone and in combination with pembrolizumab. Additionally, their IND-ready program, PY265 anti-MARCO, aims to activate the immune system in the tumor microenvironment. Pionyr Immunotherapeutics has made significant contributions to the field of immunotherapy, as evidenced by their posters, publications, and whitepapers. As part of Ikena Oncology, the company's business development team is open to discussions regarding licensing and partnerships for their pioneering programs. With a commitment to advancing cancer treatment, Pionyr Immunotherapeutics continues to make strides in developing novel therapies to combat tumors and improve patient outcomes.Generated from the website